2027 ICD-10-CM Diagnosis Code C7A.8Other malignant neuroendocrine tumors

ICD-10-CM Codes›C00–D49›C7A›C7A

ICD-10-CM C7A.8
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

C7A.8 is a billable ICD-10-CM diagnosis code for other malignant neuroendocrine tumors. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 826 through 830, 843 through 845. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 38 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Malignant neuroendocrine tumors.

For Medicare Advantage risk adjustment, C7A.8 maps to CMS-HCC Category 21 (Lymphoma and Other Cancers) under the V28 model, adding a risk factor of about 0.671 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
C7A.8
Billable Status
Yes — Valid for Submission
Code Describes
Other malignant neuroendocrine tumors
Short Description
Other malignant neuroendocrine tumors
Same as the full description in the CMS dataset.
Parent Code
C7A
Malignant neuroendocrine tumors

Code Classification

ChapterC00–D49Neoplasms
SectionC7AMalignant neuroendocrine tumors
CategoryC7AMalignant neuroendocrine tumors
This CodeC7A.8Other malignant neuroendocrine tumors

Medicare Risk Adjustment (HCC)Billing

C7A.8 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 21— Lymphoma and Other Cancers
Payment HCC · PY 2027 one of 463 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.671
community, non-dual, aged · ranges 0.493–0.739 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, and HCC 20
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 12
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 12 · ESRD (V21): HCC 12 · ESRD (V24): HCC 12
ESRD V21 weights: 0.046 dialysis, 0.156–0.194 functioning graft · ESRD V24 weights: 0.045 dialysis, 0.162–0.219 functioning graft
Part D (RxHCC)
RxHCC 22 — Prostate, Breast, Bladder, and Other Cancers and Tumors
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Carcinoma of appendix
  • Carcinoma of body of stomach
  • Carcinoma of cardia
  • Carcinoma of cervix
  • Carcinoma of duodenum
  • Carcinoma of gallbladder
  • Carcinoma of nasal cavity
  • Carcinoma of prostate
  • Carcinoma of urinary bladder
  • Enterochromaffin cell tumor of pancreas
  • Familial gastric type 1 neuroendocrine neoplasm
  • Gastric inhibitory peptide-secreting tumor of pancreas
  • Growth hormone releasing factor-secreting tumor of pancreas
  • High-grade neuroendocrine carcinoma of cervix uteri
  • High-grade neuroendocrine carcinoma of corpus uteri
  • Large cell neuroendocrine carcinoma of lung
  • Malignant glomus tumor
  • Malignant neoplasm of ampulla of Vater
  • Malignant neoplasm of cecum
  • Malignant neoplasm of hepatic duct
  • Malignant neoplasm of ileum
  • Malignant neoplasm of jejunum
  • Malignant neoplasm of pyloric antrum
  • Malignant neuroendocrine neoplasm of nasal cavity
  • Malignant perivascular epithelioid cell neoplasm
  • Metastatic well-differentiated neuroendocrine neoplasm to bone
  • Metastatic well-differentiated neuroendocrine tumor
  • Mixed ductal-neuroendocrine carcinoma of pancreas
  • Mixed neuroendocrine-non neuroendocrine neoplasm of pancreas
  • Neoplasm of cystic duct
  • Neuroendocrine carcinoma
  • Neuroendocrine carcinoma of anus
  • Neuroendocrine carcinoma of appendix
  • Neuroendocrine carcinoma of gallbladder
  • Neuroendocrine carcinoma of pancreas
  • Neuroendocrine carcinoma of thymus
  • Neuroendocrine neoplasm of appendix
  • Neuroendocrine neoplasm of ascending colon
  • Neuroendocrine neoplasm of bronchus
  • Neuroendocrine neoplasm of duodenum
  • Neuroendocrine neoplasm of gallbladder
  • Neuroendocrine neoplasm of ileum
  • Neuroendocrine neoplasm of jejunum
  • Neuroendocrine neoplasm of large intestine
  • Neuroendocrine neoplasm of liver
  • Neuroendocrine neoplasm of pancreas
  • Neuroendocrine neoplasm of rectum
  • Neuroendocrine neoplasm of sigmoid colon
  • Neuroendocrine neoplasm of transverse colon
  • Neuroendocrine neoplasm, malignant
  • Non-functioning neuroendocrine neoplasm of pancreas
  • Overlapping malignant neoplasm of stomach
  • Parathyroid hormone-related peptide-secreting tumor of pancreas
  • Primary carcinoma liver and/or biliary system
  • Primary carcinoma of body of stomach
  • Primary carcinoma of cardia
  • Primary carcinoma of cervix
  • Primary carcinoma of colon
  • Primary carcinoma of duodenum
  • Primary carcinoma of gallbladder
  • Primary carcinoma of prostate
  • Primary carcinoma of urinary bladder
  • Primary hepatic neuroendocrine carcinoma
  • Primary malignant neoplasm of ampulla of Vater
  • Primary malignant neoplasm of anal canal
  • Primary malignant neoplasm of appendix
  • Primary malignant neoplasm of body of stomach
  • Primary malignant neoplasm of cardia of stomach
  • Primary malignant neoplasm of common bile duct
  • Primary malignant neoplasm of cystic duct
  • Primary malignant neoplasm of descending colon
  • Primary malignant neoplasm of duodenum
  • Primary malignant neoplasm of gallbladder
  • Primary malignant neoplasm of ileum
  • Primary malignant neoplasm of jejunum
  • Primary malignant neoplasm of pancreatic duct
  • Primary malignant neoplasm of prostate
  • Primary malignant neoplasm of pyloric antrum
  • Primary malignant neoplasm of rectum
  • Primary malignant neuroendocrine neoplasm of ampulla of Vater
  • Primary malignant neuroendocrine neoplasm of anal canal
  • Primary malignant neuroendocrine neoplasm of anus
  • Primary malignant neuroendocrine neoplasm of appendix
  • Primary malignant neuroendocrine neoplasm of ascending colon
  • Primary malignant neuroendocrine neoplasm of biliary tract
  • Primary malignant neuroendocrine neoplasm of body of stomach
  • Primary malignant neuroendocrine neoplasm of bronchus
  • Primary malignant neuroendocrine neoplasm of cardia of stomach
  • Primary malignant neuroendocrine neoplasm of cecum
  • Primary malignant neuroendocrine neoplasm of colon
  • Primary malignant neuroendocrine neoplasm of cystic duct
  • Primary malignant neuroendocrine neoplasm of descending colon
  • Primary malignant neuroendocrine neoplasm of distal bile duct
  • Primary malignant neuroendocrine neoplasm of duodenum
  • Primary malignant neuroendocrine neoplasm of esophagus
  • Primary malignant neuroendocrine neoplasm of ileum
  • Primary malignant neuroendocrine neoplasm of jejunum
  • Primary malignant neuroendocrine neoplasm of large intestine
  • Primary malignant neuroendocrine neoplasm of lung
  • Primary malignant neuroendocrine neoplasm of pancreas
  • Primary malignant neuroendocrine neoplasm of perihilar bile duct
  • Primary malignant neuroendocrine neoplasm of pyloric antrum of stomach
  • Primary malignant neuroendocrine neoplasm of rectum
  • Primary malignant neuroendocrine neoplasm of small intestine
  • Primary malignant neuroendocrine neoplasm of uterus
  • Primary malignant perivascular epithelioid cell neoplasm
  • Primary mixed acinar endocrine-ductal carcinoma of pancreas
  • Primary neuroendocrine carcinoma of body of stomach
  • Primary neuroendocrine carcinoma of cardia of stomach
  • Primary neuroendocrine carcinoma of cervix uteri
  • Primary neuroendocrine carcinoma of colon
  • Primary neuroendocrine carcinoma of duodenum
  • Primary neuroendocrine carcinoma of esophagus
  • Primary neuroendocrine carcinoma of gallbladder
  • Primary neuroendocrine carcinoma of overlapping sites of stomach
  • Primary neuroendocrine carcinoma of pyloric antrum of stomach
  • Primary neuroendocrine carcinoma of rectum
  • Primary neuroendocrine carcinoma of small intestine
  • Primary neuroendocrine carcinoma of stomach
  • Primary small cell neuroendocrine carcinoma of prostate
  • Primary small cell neuroendocrine carcinoma of urinary bladder
  • Primary well-differentiated neuroendocrine tumor of pancreas
  • Serotonin level above reference range
  • Serotonin-producing neuroendocrine neoplasm of pancreas
  • Small cell neuroendocrine carcinoma of ovary
  • Small cell neuroendocrine carcinoma of prostate
  • Small cell neuroendocrine carcinoma of urinary bladder
  • Well-differentiated neuroendocrine tumor of ascending colon
  • Well-differentiated neuroendocrine tumor of cecum
  • Well-differentiated neuroendocrine tumor of colon
  • Well-differentiated neuroendocrine tumor of descending colon
  • Well-differentiated neuroendocrine tumor of duodenum
  • Well-differentiated neuroendocrine tumor of stomach

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to C7A.8: its own notes plus those printed at C7A and Chapter 2. A note printed at a category, block or chapter applies to every code under it.

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From C7A Malignant neuroendocrine tumors applies to 23 codes
  • malignant pancreatic islet cell tumors (C25.4)
  • Merkel cell carcinoma (C4A.-)

Use Additional Code

Add a second code, after this one, to fully describe the condition.

From C7A Malignant neuroendocrine tumors applies to 23 codes
  • code to identify any associated endocrine syndrome, such as:
  • carcinoid syndrome (E34.00)

Code Also

A second code may be needed to fully describe the condition; the note gives no sequencing direction.

From C7A Malignant neuroendocrine tumors applies to 23 codes
  • any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)

Notes

General instructions on how these codes are used.

From Chapter 2 (C00-D49) Neoplasms applies to 1,730 codes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name C7A.8, its category, or a range that includes it.

Excludes1 1

These codes carry an Excludes1 note naming C7A.8: they are not reported together with it, unless the two conditions are unrelated.

  • C75 Malignant neoplasm of other endocrine glands and related structures
    malignant neuroendocrine tumors (C7A.-) names C7A.-, which includes this code

Code Also 1

These codes say C7A.8 may also be needed to fully describe the condition. The note gives no sequencing direction.

  • E34.0 Carcinoid syndrome
    primary neuroendocrine tumors (C7A.-) names C7A.-, which includes this code

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO066
Malignant neuroendocrine tumors
Default principal diagnosis: inpatient Yes · outpatient Yes

Patient EducationClinical

Cancer

Cancer is not just one disease but many diseases. Cancer begins in your cells, which are the building blocks of your body. Usually, your body forms new cells as needed, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should.

The full article covers:

  • What is cancer?
  • What are the types of cancer?
  • How does cancer develop?
  • What are the symptoms of cancer?
  • How is cancer diagnosed?
  • What are the treatments for cancer?
  • Can cancer be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C7A.8 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
209.30 Malig neuroendo ca NOS
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About C7A.8Overview

What is the ICD-10 code for other malignant neuroendocrine tumors?

The ICD-10-CM code for other malignant neuroendocrine tumors is C7A.8 (sometimes written as C7A8). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is C7A.8 (Malignant neuroendocrine tumors) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report other malignant neuroendocrine tumors on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does C7A.8 group to?

When other malignant neuroendocrine tumors is the principal diagnosis on an inpatient stay, it groups to MS-DRG 844, 827, 829, 843, 828, 826, 830, 845, with relative weights from 0.8443 to 4.7560 depending on complications. Higher weights mean higher Medicare reimbursement.

Is C7A.8 a CC or MCC?

CMS lists C7A.8 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 38 closely related codes in its exclusion list.

Does C7A.8 need an additional code?

When the condition applies, yes. The Use Additional Code note at C7A, which applies to C7A.8, reads: code to identify any associated endocrine syndrome, such as: carcinoid syndrome (E34.00). The additional code is reported after C7A.8.

What HCC is C7A.8?

C7A.8 (other malignant neuroendocrine tumors) maps to CMS-HCC Category 21 (Lymphoma and Other Cancers), commonly written as HCC 21, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.

Does C7A.8 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, C7A.8 adds a risk adjustment factor of about 0.671 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.493 to 0.739 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, and HCC 20) supersedes it when both are reported. See the full factor table on the HCC 21 category page.